David A. Siegel Rhythm Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 9,700 shares of RYTM stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,700
Previous 12,100
19.83%
Holding current value
$1.05 Million
Previous $640,000
4.38%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding RYTM
# of Institutions
249Shares Held
63.9MCall Options Held
210KPut Options Held
575K-
Black Rock Inc. New York, NY6.74MShares$728 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$605 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.56MShares$601 Million7.68% of portfolio
-
Primecap Management CO Pasadena, CA4.88MShares$527 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$388 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $6.02B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...